CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
CytoTrack is developing the CT11™, a blood test designed to detect and monitor tumor mutations in cancer patients. This tool aims to optimize treatment decisions based on real-time genetic information, improving patient outcomes.
In Europe, approximately 1 in 2 people will get cancer in their lifetimes.
State-of-the-art cancer treatments can be tailored to the genetic make-up of a patient’s tumour, making them highly effective at fighting cancer.
However, these very expensive treatments, which cost the society €1.5bn each year, can become ineffective over time due to genetic mutations in the tumours.
Currently, there is no diagnostic tool available to regularly monitor for such mutations.CytoTrack has developed the CT11™…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
HVD BIOTECH VERTRIEBSGESELLSCHAFT MBH
Austria, WIEN
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
